X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1937) 1937
Publication (249) 249
Book Review (28) 28
Book Chapter (26) 26
Conference Proceeding (1) 1
Data Set (1) 1
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1228) 1228
hepatitis c virus (1143) 1143
hepatitis c (1015) 1015
humans (984) 984
direct-acting antivirals (773) 773
antiviral agents - therapeutic use (718) 718
gastroenterology & hepatology (633) 633
antiviral agents (599) 599
hepatitis c, chronic - drug therapy (589) 589
ribavirin (535) 535
hepatitis (501) 501
interferon (460) 460
sofosbuvir (411) 411
male (408) 408
female (390) 390
health aspects (378) 378
hepacivirus - genetics (374) 374
middle aged (373) 373
hcv (353) 353
hepacivirus - drug effects (348) 348
sustained virological response (338) 338
genotype (337) 337
drug therapy, combination (322) 322
infectious diseases (310) 310
treatment outcome (309) 309
direct-acting antiviral agents (302) 302
cirrhosis (295) 295
hepatitis c - drug therapy (281) 281
therapy (279) 279
virus-infection (269) 269
infection (265) 265
virus diseases (260) 260
adult (253) 253
direct-acting antiviral (251) 251
liver (248) 248
aged (243) 243
care and treatment (232) 232
infections (231) 231
patients (231) 231
drug therapy (229) 229
analysis (226) 226
biological response modifiers (221) 221
virology (221) 221
genotype 1 infection (214) 214
sustained virologic response (214) 214
hepatitis c, chronic - virology (213) 213
liver cirrhosis (213) 213
viruses (211) 211
direct acting antivirals (208) 208
pharmacology & pharmacy (196) 196
antiviral agents - adverse effects (192) 192
ribavirin - therapeutic use (188) 188
antiviral agents - administration & dosage (187) 187
treatment-naive patients (168) 168
digestive system diseases (165) 165
hepatocellular carcinoma (164) 164
antiviral agents - pharmacology (163) 163
hepatitis c, chronic - complications (161) 161
protease inhibitors (160) 160
pegylated interferon (159) 159
chronic hepatitis c (157) 157
daclatasvir (154) 154
hepatology (154) 154
hcv infection (153) 153
genotype 1 (152) 152
hiv (147) 147
genotypes (146) 146
medical research (144) 144
ledipasvir (141) 141
telaprevir (141) 141
plus ribavirin (140) 140
medicine & public health (138) 138
direct‐acting antivirals (137) 137
gastroenterology and hepatology (137) 137
genetic aspects (137) 137
medicine, experimental (133) 133
prevalence (133) 133
hepatitis-c virus (130) 130
genotype & phenotype (127) 127
efficacy (126) 126
liver transplantation (125) 125
immunology (120) 120
hepatocellular-carcinoma (119) 119
risk factors (119) 119
safety (119) 119
fibrosis (117) 117
hepatitis c - virology (111) 111
transplantation (111) 111
viral nonstructural proteins - antagonists & inhibitors (111) 111
sofosbuvir - therapeutic use (107) 107
antiviral therapy (106) 106
liver diseases (106) 106
microbiology (106) 106
proteases (106) 106
chronic hepatitis-c (105) 105
interferon-alpha - therapeutic use (105) 105
medicine, general & internal (101) 101
mortality (101) 101
recurrence (101) 101
treatment-naive (101) 101
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1860) 1860
Korean (36) 36
Spanish (30) 30
Hungarian (13) 13
German (10) 10
Japanese (9) 9
French (7) 7
Russian (5) 5
Chinese (1) 1
Persian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 6, pp. 1511 - 1522
Summary Failure to respond to the approved combinations of multiple direct-acting antiviral agents is relatively low in hepatitis C virus treatment... 
Gastroenterology and Hepatology | Daclatasvir | Simeprevir | Treatment | Resistance-associated variants | Ledipasvir | Interferon | Hepatitis C virus | Sofosbuvir | Direct-acting antivirals | Resistanceassociated variants | CHRONIC HCV | CHRONIC HEPATITIS-C | REAL-WORLD | PEGYLATED INTERFERON | DOUBLE-BLIND | GENOTYPE 1 INFECTION | INTERFERON-ALPHA 2A | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | DACLATASVIR PLUS SOFOSBUVIR | Uridine Monophosphate - administration & dosage | Humans | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Carbamates - administration & dosage | Simeprevir - administration & dosage | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Treatment Failure | Protease Inhibitors - administration & dosage | Fluorenes - administration & dosage | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Clinical Trials as Topic | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Interferons - administration & dosage | Drug Resistance, Viral - genetics | Anilides - administration & dosage | Sofosbuvir - administration & dosage | Uridine Monophosphate - analogs & derivatives | Macrocyclic Compounds - administration & dosage | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Development and progression | Protease inhibitors | Drug resistance | Hepatitis C | Proteases
Journal Article
Antiviral Research, ISSN 0166-3542, 08/2014, Volume 108, Issue 1, pp. 181 - 191
Journal Article
Clinical Obstetrics and Gynecology, ISSN 0009-9201, 12/2019, Volume 62, Issue 4, pp. 823 - 834
Between 70 and 170 million people worldwide are infected with hepatitis C virus (HCV) which frequently causes chronic liver disease and cirrhosis. There are... 
CLEARANCE | VIRUS-INFECTION | ENTRY | direct-acting antiviral agents | hepatitis C | pregnancy | HCV | UPDATE | OBSTETRICS & GYNECOLOGY | Antiviral agents | Usage | Hepatitis C | Drug therapy | Innovations
Journal Article
Hepatology, ISSN 0270-9139, 01/2018, Volume 67, Issue 1, pp. 48 - 55
Journal Article
by Chen, ZW and Li, H and Ren, H and Hu, P
SCIENTIFIC REPORTS, ISSN 2045-2322, 02/2016, Volume 6
Direct-acting antiviral agents (DAAs) against hepatitis C virus (HCV) proteins open a whole new era for anti-HCV therapy, but DAA resistance associated... 
GENOTYPE 1 | SERINE-PROTEASE INHIBITORS | TELAPREVIR | HEPATITIS-C VIRUS | CLINICAL-TRIAL | MULTIDISCIPLINARY SCIENCES | POLYMERASE INHIBITOR | DIRECT-ACTING ANTIVIRALS | MUTATIONS | IN-VITRO RESISTANCE | TREATMENT-NAIVE PATIENTS
Journal Article
Digestive Diseases and Sciences, ISSN 0163-2116, 11/2019, Volume 64, Issue 11, pp. 3328 - 3336
Journal Article
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 2016, Volume 14, Issue 12, pp. 1821 - 1830.e6
Journal Article